Trial Profile
A study assessing efficacy of Xience/Promus versus Cypher in patients receiving percutaneous intervention from the EXCELLENT (Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing) Registry.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Oct 2016
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Sirolimus (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- Acronyms EXCELLENT
- 09 Oct 2016 New trial record